Published in Brain Behav Immun on September 03, 2008
Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry (2009) 8.74
The mysterious motivational functions of mesolimbic dopamine. Neuron (2012) 3.22
Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology (2011) 2.31
Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology (2010) 2.29
The vascular depression hypothesis: mechanisms linking vascular disease with depression. Mol Psychiatry (2013) 2.17
Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther (2011) 2.12
Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels. Biol Psychiatry (2009) 1.93
Healthy young women with serotonin transporter SS polymorphism show a pro-inflammatory bias under resting and stress conditions. Brain Behav Immun (2009) 1.61
Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety (2013) 1.48
Immune suppression and immune activation in depression. Brain Behav Immun (2010) 1.48
Depression and immunity: a role for T cells? Brain Behav Immun (2009) 1.40
Eating ourselves to death (and despair): the contribution of adiposity and inflammation to depression. Prog Neurobiol (2010) 1.38
Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. Brain Behav Immun (2012) 1.36
Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise. Front Neuroendocrinol (2012) 1.35
Prolonged restraint stress increases IL-6, reduces IL-10, and causes persistent depressive-like behavior that is reversed by recombinant IL-10. PLoS One (2013) 1.18
Tyrosine metabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrations. Brain Behav Immun (2012) 1.11
Recommendations for high-priority research on cancer-related fatigue in children and adults. J Natl Cancer Inst (2013) 1.11
Alcoholism and inflammation: neuroimmunology of behavioral and mood disorders. Brain Behav Immun (2010) 1.11
The possible role of the kynurenine pathway in anhedonia in adolescents. J Neural Transm (Vienna) (2011) 0.99
Molecular signatures of peripheral blood mononuclear cells during chronic interferon-α treatment: relationship with depression and fatigue. Psychol Med (2011) 0.94
Malaise, melancholia and madness: the evolutionary legacy of an inflammatory bias. Brain Behav Immun (2013) 0.89
Gender differences in the relationship between symptoms of depression and high-sensitivity CRP. Int J Obes (Lond) (2013) 0.89
Selective hyper-responsiveness of the interferon system in major depressive disorders and depression induced by interferon therapy. PLoS One (2012) 0.88
Peripheral anti-inflammatory effects explain the ginsenosides paradox between poor brain distribution and anti-depression efficacy. J Neuroinflammation (2011) 0.88
Effort-related motivational effects of the pro-inflammatory cytokine interleukin 1-beta: studies with the concurrent fixed ratio 5/ chow feeding choice task. Psychopharmacology (Berl) (2013) 0.87
Ascending caudal medullary catecholamine pathways drive sickness-induced deficits in exploratory behavior: brain substrates for fatigue? Brain Behav Immun (2010) 0.85
Neurobehavioral effects of interferon-α in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine. Neuropsychopharmacology (2012) 0.84
The neurobiological pathogenesis of poststroke depression. ScientificWorldJournal (2014) 0.82
Prevalence of suicidality among Hispanic and African American veterans following surgery. Am J Public Health (2014) 0.81
Psychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities. Front Immunol (2015) 0.81
Depressive symptoms among cancer patients in a Philippine tertiary hospital: prevalence, factors, and influence on health-related quality of life. J Palliat Med (2013) 0.80
Mast cells' involvement in inflammation pathways linked to depression: evidence in mastocytosis. Mol Psychiatry (2016) 0.79
Caregiver-reported neuropsychiatric symptoms in patients undergoing treatment for head and neck cancer: a pilot study. Cancer Nurs (2014) 0.79
Interleukin-6 and tumor necrosis factor-α are associated with quality of life-related symptoms in pulmonary arterial hypertension. Ann Am Thorac Soc (2015) 0.79
Association study between functional polymorphisms in the TNF-alpha gene and obsessive-compulsive disorder. Arq Neuropsiquiatr (2012) 0.78
The VMAT-2 inhibitor tetrabenazine affects effort-related decision making in a progressive ratio/chow feeding choice task: reversal with antidepressant drugs. PLoS One (2014) 0.78
Concomitant interferon alpha stimulation and TLR3 activation induces neuronal expression of depression-related genes that are elevated in the brain of suicidal persons. PLoS One (2013) 0.78
Effort-related motivational effects of the pro-inflammatory cytokine interleukin-6: pharmacological and neurochemical characterization. Psychopharmacology (Berl) (2016) 0.78
Development of a murine animal model of depression for repeated dosing with human interferon alpha. Indian J Psychiatry (2011) 0.77
Cytomegalovirus Antibody Elevation in Bipolar Disorder: Relation to Elevated Mood States. Neural Plast (2015) 0.77
Patients with blepharitis are at elevated risk of anxiety and depression. PLoS One (2013) 0.77
Psychoneuroimmunology: the example of psoriasis. G Ital Dermatol Venereol (2010) 0.77
Taking the Perspective that a Depressive State Reflects Inflammation: Implications for the Use of Antidepressants. Front Psychol (2012) 0.76
Time-dependent behavioral, neurochemical, and metabolic dysregulation in female C57BL/6 mice caused by chronic high-fat diet intake. Physiol Behav (2016) 0.76
Pharmacological Properties and Molecular Mechanisms of Thymol: Prospects for Its Therapeutic Potential and Pharmaceutical Development. Front Pharmacol (2017) 0.76
Transcriptomic Modification in the Cerebral Cortex following Noninvasive Brain Stimulation: RNA-Sequencing Approach. Neural Plast (2016) 0.75
Prevalence and determinants of fatigue in patients with moderate to severe chronic GvHD. Bone Marrow Transplant (2016) 0.75
The emergence of obsessive compulsive and compulsive buying symptomatology after acute stress and short-term use of ribavirin: case reports. Ther Adv Psychopharmacol (2013) 0.75
Effects of lisdexamfetamine and s-citalopram, alone and in combination, on effort-related choice behavior in the rat. Psychopharmacology (Berl) (2015) 0.75
Affective neuronal selection: the nature of the primordial emotion systems. Front Psychol (2013) 0.75
Association between inflammatory cytokines and the risk of post-stroke depression, and the effect of depression on outcomes of patients with ischemic stroke in a 2-year prospective study. Exp Ther Med (2016) 0.75
Prenatal maternal depression is associated with offspring inflammation at 25 years: a prospective longitudinal cohort study. Transl Psychiatry (2016) 0.75
Association between serotonin transporter polymorphisms (5-HTTLPR) and the MADRS Dysphoria, Retardation, and Vegetative Subscale scores in the treatment of depression. Neuropsychiatr Dis Treat (2017) 0.75
Retracted Relationship between inflammatory cytokines and risk of depression, and effect of depression on the prognosis of high grade glioma patients. J Neurooncol (2015) 0.75
Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science (2003) 28.61
Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci (1986) 18.17
From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci (2008) 15.90
Anterior cingulate cortex, error detection, and the online monitoring of performance. Science (1998) 10.91
Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol (2005) 8.49
Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation (2003) 8.29
Multiple dopamine functions at different time courses. Annu Rev Neurosci (2007) 6.18
Inflammation and cancer: how hot is the link? Biochem Pharmacol (2006) 5.17
Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry (2001) 4.70
Childhood maltreatment predicts adult inflammation in a life-course study. Proc Natl Acad Sci U S A (2007) 4.58
Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun (2006) 4.55
The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry (2007) 4.51
Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med (2001) 4.39
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet (2006) 4.26
Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience (1991) 4.05
Why rejection hurts: a common neural alarm system for physical and social pain. Trends Cogn Sci (2004) 3.95
A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci U S A (2003) 3.82
Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev (1998) 3.66
Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry (2006) 3.33
Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry (2008) 3.28
Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology (2002) 3.24
Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem (2002) 3.14
The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun (2001) 2.89
Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry (2002) 2.87
Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry (2004) 2.83
Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch Gen Psychiatry (2008) 2.82
Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev (1992) 2.79
Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun (2007) 2.75
Beyond the reward hypothesis: alternative functions of nucleus accumbens dopamine. Curr Opin Pharmacol (2005) 2.57
Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry (1995) 2.35
The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry (2007) 2.34
Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther (1988) 2.29
Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. N Engl J Med (1999) 2.14
The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology (2006) 2.12
Nucleus accumbens dopamine and the regulation of effort in food-seeking behavior: implications for studies of natural motivation, psychiatry, and drug abuse. J Pharmacol Exp Ther (2003) 2.10
Neuropathology and neurodegeneration in human immunodeficiency virus infection. Pathogenesis of HIV-induced lesions of the brain, correlations with HIV-associated disorders and modifications according to treatments. Clin Neuropathol (2001) 2.09
Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry (2003) 2.05
Endotoxin produces a depressive-like episode in rats. Brain Res (1996) 2.04
IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry (2005) 1.98
Consensus paper of the WFSBP Task Force on Biological Markers: biological markers in depression. World J Biol Psychiatry (2007) 1.93
Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs (2005) 1.93
Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry (2003) 1.90
The metabolic topography of parkinsonism. J Cereb Blood Flow Metab (1994) 1.89
Inflammatory process in Parkinson's disease: role for cytokines. Curr Pharm Des (2005) 1.87
Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe. Arch Gen Psychiatry (2005) 1.85
Fatigue and basal ganglia. J Neurol Sci (2000) 1.82
Anterior cingulate activation and error processing during interferon-alpha treatment. Biol Psychiatry (2005) 1.80
Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry (2008) 1.80
Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol Psychiatry (2008) 1.73
p38 MAPK activation elevates serotonin transport activity via a trafficking-independent, protein phosphatase 2A-dependent process. J Biol Chem (2005) 1.71
TNFalpha signaling in depression and anxiety: behavioral consequences of individual receptor targeting. Biol Psychiatry (2006) 1.67
Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J Neurosci (2003) 1.63
Overactive action monitoring in obsessive-compulsive disorder: evidence from functional magnetic resonance imaging. Psychol Sci (2003) 1.63
Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology (2007) 1.63
Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry (2005) 1.58
MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor-alpha-induced insulin resistance. J Biol Chem (2007) 1.53
Pathophysiology of Parkinson's disease: the MPTP primate model of the human disorder. Ann N Y Acad Sci (2003) 1.52
Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression. Biol Psychiatry (2007) 1.51
Metabolic correlates of levodopa response in Parkinson's disease. Neurology (2001) 1.50
Retracted Polychlorinated biphenyls induce proinflammatory cytokine release and dopaminergic dysfunction: protection in interleukin-6 knockout mice. J Neuroimmunol (2007) 1.48
Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J (2002) 1.45
HIV dementia: the role of the basal ganglia and dopaminergic systems. J Psychopharmacol (2000) 1.44
Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry (2005) 1.41
Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease. Ann Neurol (1990) 1.41
Neonatal endotoxin exposure alters the development of the hypothalamic-pituitary-adrenal axis: early illness and later responsivity to stress. J Neurosci (1995) 1.38
Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology (Berl) (2000) 1.35
IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C. Brain Behav Immun (2008) 1.30
Functional neuroanatomy of the basal ganglia in Parkinson's disease. Adv Neurol (2003) 1.28
The role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry (2006) 1.27
Voltammetric study of the control of striatal dopamine release by glutamate. J Neurochem (2004) 1.27
Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther (2007) 1.26
Personality from a controlled processing perspective: an fMRI study of neuroticism, extraversion, and self-consciousness. Cogn Affect Behav Neurosci (2005) 1.24
Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation. Am J Psychiatry (2001) 1.22
Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol Appl Neurobiol (2005) 1.21
Lower dopamine transporter binding potential in striatum during depression. Neuroreport (2001) 1.20
Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients. Psychosom Med (2001) 1.20
Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res (1997) 1.19
C-reactive protein and atherogenesis: from fatty streak to clinical event. Atherosclerosis (2007) 1.19
Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol Psychiatry (2002) 1.18
Exacerbated physical fatigue and mental fatigue in Parkinson's disease. Mov Disord (2001) 1.18
Differential effects of lipopolysaccharide on pup retrieving and nest building in lactating mice. Brain Behav Immun (1997) 1.17
Anterior cingulate activation in high trait anxious subjects is related to altered error processing during decision making. Biol Psychiatry (2004) 1.16
Activated p38 MAPK is associated with decreased CSF 5-HIAA and increased maternal rejection during infancy in rhesus monkeys. Mol Psychiatry (2007) 1.14
Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain? J Neural Transm (Vienna) (2006) 1.12
Dopamine and depression. J Neural Transm Gen Sect (1993) 1.11
Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex. J Neuroinflammation (2005) 1.10
Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: role of nitric oxide as a signal crossing the blood-brain barrier. Brain Res (2003) 1.10
Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled, crossover study. Mov Disord (2003) 1.09
Clinical and psychometric correlates of dopamine D2 binding in depression. Psychol Med (1997) 1.08
Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. Oncol Nurs Forum (2002) 1.06
Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease. Am J Psychiatry (2002) 1.06
Dopamine D2 receptors in depression measured with single photon emission computed tomography. Biol Psychiatry (1994) 1.06
Influence of parenting style on the offspring's behaviour and CSF monoamine metabolite levels in crossfostered and noncrossfostered female rhesus macaques. Behav Brain Res (2006) 1.05
Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation. Mol Psychiatry (2001) 1.05
Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain. Eur Neuropsychopharmacol (2000) 1.04
A potential role for interferon-alpha in the pathogenesis of HIV-associated dementia. Brain Behav Immun (1995) 1.03
The two faces of Eve: dopamine's modulation of wakefulness and sleep. Neurology (2004) 1.01
Regulation of noradrenergic function by inflammatory cytokines and depolarization. J Neurochem (2003) 0.98
Potential time course of human immunodeficiency virus type 1-associated minor motor deficits: electrophysiologic and positron emission tomography findings. Arch Neurol (2000) 0.97
HIV Dementia Scale and psychomotor slowing--the best methods in screening for neuro-AIDS. J Neuropsychiatry Clin Neurosci (2005) 0.97